SEARCH:   Advanced

Blood, 1 July 2006, Vol. 108, No. 1, pp. 97-102. Prepublished online as a Blood First Edition Paper on March 14, 2006; DOI 10.1182/blood-2006-01-0066. This Article Full Text Full Text (PDF) All Versions of this Article: 2006-01-0066v1 108/1/97    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Coustan-Smith, E. Articles by Campana, D. Search for Related Content PubMed PubMed Citation Articles by Coustan-Smith, E. Articles by Campana, D. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Elaine Coustan-Smith, Raul C. Ribeiro, Patricia Stow, Yinmei Zhou, Ching-Hon Pui, Gaston K. Rivera, Francisco Pedrosa, and Dario Campana From the Departments of Hematology-Oncology, Biostatistics, and Pathology, and International Outreach Program, St Jude Children's Research Hospital, Memphis, TN; the Department of Pediatrics, University of Tennessee, Memphis, TN; and Centro de Hematologia e Oncologia de Pernambuco e Instituto Materno-Infantil de Pernambuco, Recife, Brazil. Bone marrow normal lymphoid progenitors (CD19+, CD10+, and/or CD34+) are exquisitely sensitive to corticosteroids and other antileukemic drugs. We hypothesized that, in patients with B-lineage acute lymphoblastic leukemia (ALL), cells with this phenotype detected early in treatment should be leukemic rather than normal. We therefore developed a simple and inexpensive flow cytometric assay for such cells and prospectively applied it to bone marrow samples collected on day 19 from 380 children with B-lineage ALL. In 211 patients (55.5%), these cells represented 0.01% or more of the mononuclear cells; results correlated remarkably well with those of more complex flow cytometric and molecular minimal residual disease (MRD) evaluations. Among 84 uniformly treated children, the 10-year incidence of relapse or remission failure was 28.8% ± 7.1% (SE) for the 42 patients with 0.01% or more leukemic cells on day 19 detected by the simplified assay versus 4.8% ± 3.3% for the 42 patients with lower levels (P = .003). These assay results were the strongest predictor of outcome, even after adjustment for competing clinicobiologic variables. Thus, this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure. (Blood. 2006;108:97-102) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood, September 1, 2007; 110(5): 1607 - 1611. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020